V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10325027 | 10039616 | 1.67 | 66.8 | null | 2022-03-04 | 2022-03-24 | Avelumab | 02 | null | AVELUMAB | 100512860 |
| 10325047 | 10039617 | 1.6 | 54 | Palliative (P) | 2017-01-24 | 2017-01-24 | BORTEZOMIB + THALIDOMIDE | 02 | N | BORTEZOMIB + THALIDOMIDE | 101591204 |
| 10325053 | 10039618 | 1.72 | 71.6 | null | 2019-07-19 | 2019-07-19 | Temozolomide + RT | 02 | null | TEMOZOLOMIDE | 101399069 |
| 10325055 | 10039619 | 1.68 | 75.3 | Curative (C) | null | 2018-04-05 | Acalabrutinib | 99 | N | ACALABRUTINIB | 101299208 |
| 10325161 | 10039620 | null | 0 | Adjuvant (A) | 2017-11-18 | 2017-11-18 | CHOP R - 21 days | 02 | N | CHOP R | 100113996 |
| 10325217 | 10039621 | 1.62 | 82.9 | null | 2018-11-01 | 2018-11-01 | Sunitinib | 02 | null | CYCLOPHOSPHAMIDE + THALIDOMIDE | 101008832 |
| 10325283 | 10039622 | 1.7 | 62 | null | 2020-11-20 | 2020-12-17 | FLUOROURACIL | 02 | null | FLUOROURACIL | 101155610 |
| 10325335 | 10039623 | 1.69 | 66.3 | null | 2018-09-08 | 2018-09-08 | Folfirinox | 02 | null | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 100154863 |
| 10325362 | 10039624 | 1.59 | 85.2 | null | 2021-01-31 | 2021-02-03 | CISPLATIN + VINORELBINE | 02 | null | CYTARABINE | 101732062 |
| 10325373 | 10039625 | 1.65 | 72.15 | null | 2022-02-22 | 2022-03-04 | R Chlorambucil | 02 | null | CHLORAMBUCIL + RITUXIMAB | 100923573 |
| 10325469 | 10039627 | 1.71 | 51 | Curative (C) | 2019-01-13 | 2019-01-13 | CISPLATIN + FLUOROURACIL | 02 | N | DABRAFENIB + TRAMETINIB | 100944291 |
| 10325518 | 10039628 | 1.67 | 83.2 | null | 2019-01-07 | 2019-01-16 | Avelumab | 02 | null | AVELUMAB | 101583686 |
| 10325540 | 10039629 | 1.72 | null | Adjuvant (A) | null | 2018-11-06 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 2 | N | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 100900869 |
| 10325644 | 10039631 | 1.52 | 0 | 03 | 2017-11-26 | 2017-11-26 | Trial Unspecified | 02 | Y | VENETOCLAX | 101855688 |
| 10325710 | 10039632 | 1.59 | 67.25 | Adjuvant (A) | 2017-10-27 | 2018-05-19 | CISPLATIN + VINORELBINE | 02 | N | CLADRIBINE | 101215798 |
| 10325724 | 10039633 | 1.7 | 65 | 02 | 2019-12-21 | 2020-01-04 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | N | CYCLOPHOSPHAMIDE + THALIDOMIDE | 101519240 |
| 10325922 | 10039634 | 1.53 | null | Adjuvant (A) | 2020-02-16 | 2020-03-01 | Venetoclax | null | null | PAZOPANIB | 100559810 |
| 10325944 | 10039635 | 0 | 80.6 | Neo-adjuvant (N) | 2017-09-13 | 2017-09-13 | FEC + DOCETAXEL | 02 | N | CVP R | 100444455 |
| 10326059 | 10039636 | 1.65 | 77.9 | null | 2022-04-22 | 2022-05-14 | Carboplatin + Vinorelbine Oral | 02 | null | CARBOPLATIN + VINORELBINE | 101409616 |
| 10326145 | 10039637 | 1.79 | null | Palliative (P) | 2019-01-02 | 2019-04-03 | Temozolomide + RT | N | N | TEMOZOLOMIDE | 100592486 |
| 10326151 | 10039638 | 0 | 72 | null | 2018-02-17 | 2018-02-18 | Avelumab | 02 | null | AVELUMAB | 100266228 |
| 10326328 | 10039642 | 1.53 | 63.6 | Curative (C) | 2019-01-10 | 2019-01-25 | Cytarabine Low Dose | 02 | null | CYCLOPHOSPHAMIDE + THALIDOMIDE | 100268887 |
| 10326340 | 10039643 | 1.72 | 79.3 | Palliative (P) | 2022-01-20 | 2022-02-11 | CHOP - 21 days | 02 | N | CISPLATIN + FLUOROURACIL | 100362469 |
| 10326468 | 10039645 | 1.67 | 55.2 | null | 2022-03-19 | 2022-03-28 | Folfirinox | 02 | null | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 100307281 |
| 10326531 | 10039646 | 1.72 | 64.7 | Disease modification (D) | null | 2018-06-22 | Acalabrutinib | 02 | null | ACALABRUTINIB | 100506387 |
| 10326557 | 10039647 | 1.66 | 70.9 | null | 2018-12-07 | 2018-12-07 | Folfirinox | 02 | null | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 100514030 |
| 10326560 | 10039648 | 1.58 | 73.6 | null | 2014-11-15 | 2014-11-15 | DABRAFENIB + TRAMETINIB | 02 | null | SUNITINIB | 101352456 |
| 10326765 | 10039649 | 1.77 | 81.2 | 03 | 2017-03-02 | 2017-07-16 | Palbociclib | N | null | PALBOCICLIB | 101260489 |
| 10326792 | 10039650 | 0 | 79 | Palliative (P) | 2017-05-23 | 2017-06-01 | Acalabrutinib | 02 | N | ACALABRUTINIB | 101783573 |
| 10326810 | 10039651 | 1.68 | 98 | null | 2017-07-10 | 2017-07-10 | Acalabrutinib | N | null | ACALABRUTINIB | 100209077 |
| 10326909 | 10039653 | 1.52 | 85 | Palliative (P) | 2016-08-01 | 2016-08-03 | CYCLOPHOSPHAMIDE + THALIDOMIDE | null | N | DABRAFENIB + TRAMETINIB | 100048468 |
| 10326978 | 10039654 | 1.66 | 70.7 | null | 2018-11-16 | 2018-12-06 | Trial Unspecified | 02 | N | VENETOCLAX | 100769858 |
| 10327037 | 10039655 | 1.71 | 57.5 | Curative (C) | 2019-11-02 | 2019-11-17 | NIVOLUMAB | 02 | N | NIVOLUMAB | 101036610 |
| 10327041 | 10039656 | 1.72 | 120 | Neo-adjuvant (N) | 2019-07-20 | 2019-08-07 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | N | CISPLATIN + FLUOROURACIL | 101044919 |
| 10327160 | 10039658 | 1.59 | 55 | null | 2019-01-28 | 2019-02-04 | CHOP - 21 days | 02 | null | BUSULFAN | 101219963 |
| 10327208 | 10039660 | 1.57 | 57.15 | Neo-adjuvant (N) | 2016-11-03 | 2016-11-05 | Irinotecan + Modified De Gramont | 02 | N | FLUOROURACIL + IRINOTECAN | 100731818 |
| 10327284 | 10039662 | 1.68 | 73.6 | null | 2018-07-27 | 2018-08-03 | CHOP R | 02 | null | CHOP R | 100949553 |
| 10327469 | 10039665 | null | 74 | 03 | null | 2016-09-10 | Cladribine (subcut) 5 days | 02 | N | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 100314293 |
| 10327521 | 10039666 | 1.6 | 55.7 | Curative (C) | 2020-08-30 | 2020-08-30 | Folfirinox | 02 | Y | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 100946076 |
| 10327584 | 10039667 | 1.7 | 103.6 | 03 | 2020-02-12 | 2020-03-04 | BORTEZOMIB + THALIDOMIDE | 02 | N | BORTEZOMIB + THALIDOMIDE | 100080710 |
| 10327623 | 10039668 | 1.6 | 71.75 | Palliative (P) | 2020-08-23 | 2020-09-11 | IPILIMUMAB + NIVOLUMAB | 02 | N | IPILIMUMAB + NIVOLUMAB | 101859539 |
| 10327625 | 10039669 | 1.77 | 75.7 | Curative (C) | 2017-03-25 | 2017-04-04 | Capecitabine + Cisplatin | N | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 100216747 |
| 10327725 | 10039670 | 1.72 | 83.6 | Palliative (P) | 2019-07-25 | 2019-08-14 | NIVOLUMAB | 02 | N | NIVOLUMAB | 100401088 |
| 10327773 | 10039672 | null | 0 | null | 2016-06-26 | 2016-07-01 | NIVOLUMAB | 02 | null | NIVOLUMAB | 101226190 |
| 10327779 | 10039673 | 1.65 | null | Disease modification (D) | 2018-08-26 | 2018-09-10 | Mitomycin Intravesical | 02 | N | MITOMYCIN INTRAVESICULAR | 100557258 |
| 10327797 | 10039674 | 1.64 | 65 | null | 2019-05-28 | 2019-05-30 | Acalabrutinib | 02 | null | ACALABRUTINIB | 100309726 |
| 10327808 | 10039675 | 1.55 | 48 | Curative (C) | 2019-01-21 | 2019-01-29 | Bortezomib +/- Dexamethasone | 02 | null | BORTEZOMIB | 100579382 |
| 10327843 | 10039676 | 1.8 | 79.7 | Adjuvant (A) | 2021-10-01 | 2021-10-19 | CHOP | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 100922357 |
| 10327900 | 10039677 | 1.76 | 79.9 | 03 | 2019-09-28 | 2019-09-28 | CISPLATIN + FLUOROURACIL | 02 | N | CYTARABINE | 100729197 |
| 10327920 | 10039678 | 1.79 | 83 | 03 | 2021-10-31 | 2021-10-31 | BORTEZOMIB + THALIDOMIDE | 02 | null | BORTEZOMIB + THALIDOMIDE | 101454638 |